UnitedHealth Group Incorporated (UNH)
UnitedHealth Group (UNH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
UnitedHealth (UNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shareholders urge UnitedHealth to analyze impact of healthcare denials
UnitedHealth Group shareholders on Wednesday said they requested the company prepare a report on the costs and public health impact related to its "practices that limit or delay access to healthcare."
Final Trades: Apollo, UnitedHealth, Boston Scientific and the IYF
The Investment Committee give you their top stocks to watch for the second half.
UnitedHealth Group (UNH) Rises But Trails Market: What Investors Should Know
UnitedHealth Group (UNH) closed the most recent trading day at $513.67, moving +0.13% from the previous trading session.
Why UnitedHealth Group Stock Lost 17% in December
Shares of UnitedHealth Group (UNH 1.83%) were pulling back in December due to a backlash against the company following the murder of one of its executives and reports of a potential crackdown on pharmacy benefit managers (PBMs), including UnitedHealth's OptumRx.
Here's Why UnitedHealth Group (UNH) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
UnitedHealth Group CEO Reportedly Says Company Will Hit Financial Records: Exec's Murder, Public Outcry Are Backdrop For Q4 Earnings
The death of UnitedHealthcare CEO Brian Thompson shocked the health insurance industry and could be on the minds of investors and analysts when the insurance company's parent UnitedHealth Group UNH reports fourth-quarter financial results on Jan. 16.
Is UnitedHealth Group Stock a Buy?
The U.S. healthcare system is a behemoth -- in 2023, industrywide expenditures totaled $4.9 trillion, or $14,570 per American. UnitedHealth Group (UNH -0.23%) is at the industry's center.
Amid Rage At Its Industry, UnitedHealthcare Faces 2025 Pricing Challenges
As UnitedHealth Group grapples with the horrific loss of the head of is health insurance business, the company faces rising costs and tough negotiations with governments it works with to provide elderly and poor Americans their health benefits.
Midnight Sun Mining: illuminating the Zambian-Congo copperbelt with pursuit of high-value deposits
UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) and Amedisys (NASDAQ:AMED) have agreed to extend the deadline for their $3.3 billion merger, facing ongoing scrutiny from the US Department of Justice (DOJ). The companies announced in a regulatory filing that the merger deadline will now be extended to 10 days after a final court decision is issued or December 31, 2025, whichever comes first. This development follows a lawsuit filed over a month ago by the DOJ and attorneys general from Maryland, New Jersey, and New York to block the merger. Regulators argue that the deal would reduce competition in the home health services market, potentially harming patients, insurers, and nurses. The original deadline for the merger was set for today. Under a new waiver agreement, the companies have adjusted financial terms, including a regulatory break fee of $275 million, which could rise to $325 million if specific asset divestitures are not completed by May 1. Other modifications to the agreement include changes to operational restrictions and conditions tied to government approvals. UnitedHealth first announced plans to acquire Amedisys in June 2023, seeking to integrate the home health and hospice care provider into its operations. Despite the regulatory challenges, the companies remain committed to completing the deal, which they believe will deliver significant synergies and growth opportunities. Shares of Amedisys added 4.7% at $90 on the update, while UnitedHealth stock was down 0.5% at about $508.
UnitedHealth and Amedisys extend $3.3B merger deadline amid DOJ scrutiny
UnitedHealth Group Inc (NYSE:UNH, ETR:UNH) and Amedisys (NASDAQ:AMED) have agreed to extend the deadline for their $3.3 billion merger, facing ongoing scrutiny from the US Department of Justice (DOJ). The companies announced in a regulatory filing that the merger deadline will now be extended to 10 days after a final court decision is issued or December 31, 2025, whichever comes first.
UnitedHealth: Don't Let The Market Fool You
Panic sellers have bailed out of UnitedHealth stock as the leading healthcare sector leader took a significant hammering. Despite structural headwinds, UNH's diversified business model, particularly its profitable Optum segment, underpins its solid profitability and positions it well against smaller peers. UNH's valuation has dropped below its 10-year average, making it reasonably valued and an attractive opportunity for aggressive dip-buying.
